PMC:7556165 / 71328-71683 JSONTXT

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T196","span":{"begin":129,"end":136},"obj":"Chemical"}],"attributes":[{"id":"A196","pred":"chebi_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017)."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T398","span":{"begin":67,"end":75},"obj":"Species"}],"attributes":[{"id":"A398","pred":"ncbi_taxonomy_id","subj":"T398","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017)."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T422","span":{"begin":0,"end":355},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017)."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1965","span":{"begin":76,"end":84},"obj":"Species"},{"id":"1966","span":{"begin":316,"end":324},"obj":"Species"},{"id":"1971","span":{"begin":210,"end":216},"obj":"Chemical"},{"id":"1973","span":{"begin":67,"end":75},"obj":"Disease"},{"id":"1974","span":{"begin":330,"end":334},"obj":"Disease"}],"attributes":[{"id":"A1965","pred":"pubann:denotes","subj":"1965","obj":"Tax:9606"},{"id":"A1966","pred":"pubann:denotes","subj":"1966","obj":"Tax:9606"},{"id":"A1973","pred":"pubann:denotes","subj":"1973","obj":"MESH:C000657245"},{"id":"A1974","pred":"pubann:denotes","subj":"1974","obj":"MESH:D012128"}],"text":"Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017)."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T459","span":{"begin":129,"end":136},"obj":"Body_part"}],"attributes":[{"id":"A459","pred":"fma_id","subj":"T459","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017)."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T420","span":{"begin":67,"end":75},"obj":"Disease"},{"id":"T421","span":{"begin":330,"end":334},"obj":"Disease"}],"attributes":[{"id":"A420","pred":"mondo_id","subj":"T420","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A421","pred":"mondo_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1965","span":{"begin":76,"end":84},"obj":"Species"},{"id":"1966","span":{"begin":316,"end":324},"obj":"Species"},{"id":"1971","span":{"begin":210,"end":216},"obj":"Chemical"},{"id":"1973","span":{"begin":67,"end":75},"obj":"Disease"},{"id":"1974","span":{"begin":330,"end":334},"obj":"Disease"}],"attributes":[{"id":"A1965","pred":"tao:has_database_id","subj":"1965","obj":"Tax:9606"},{"id":"A1966","pred":"tao:has_database_id","subj":"1966","obj":"Tax:9606"},{"id":"A1973","pred":"tao:has_database_id","subj":"1973","obj":"MESH:C000657245"},{"id":"A1974","pred":"tao:has_database_id","subj":"1974","obj":"MESH:D012128"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T422","span":{"begin":0,"end":355},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017)."}